A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Martin van den Bent, Analia Azaro, Filip De Vos, Juan Sepulveda, W. K. Alfred Yung, Patrick Y. Wen, Andrew B. Lassman, Markus Joerger, Ghazaleh Tabatabai, Jordi Rodon, Ralph Tiedt, Sylvia Zhao, Tiina Kirsilae, Yi Cheng, Sergio Vicente, O. Alejandro Balbin, Hefei Zhang, Wolfgang Wick

Open source

DOI: 10.1007/s11060-019-03337-2
Published: 2019-11-27
Container: Journal of Neuro-Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11060-019-03337-2,
  title = {A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma},
  author = {Martin van den Bent and Analia Azaro and Filip De Vos and Juan Sepulveda and W. K. Alfred Yung and Patrick Y. Wen and Andrew B. Lassman and Markus Joerger and Ghazaleh Tabatabai and Jordi Rodon and Ralph Tiedt and Sylvia Zhao and Tiina Kirsilae and Yi Cheng and Sergio Vicente and O. Alejandro Balbin and Hefei Zhang and Wolfgang Wick},
  year = {2019},
  journal = {Journal of Neuro-Oncology},
  doi = {10.1007/s11060-019-03337-2},
  url = {https://doi.org/10.1007/s11060-019-03337-2}
}

RIS

TY  - JOUR
TI  - A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
AU  - Martin van den Bent
AU  - Analia Azaro
AU  - Filip De Vos
AU  - Juan Sepulveda
AU  - W. K. Alfred Yung
AU  - Patrick Y. Wen
AU  - Andrew B. Lassman
AU  - Markus Joerger
AU  - Ghazaleh Tabatabai
AU  - Jordi Rodon
AU  - Ralph Tiedt
AU  - Sylvia Zhao
AU  - Tiina Kirsilae
AU  - Yi Cheng
AU  - Sergio Vicente
AU  - O. Alejandro Balbin
AU  - Hefei Zhang
AU  - Wolfgang Wick
PY  - 2019
JO  - Journal of Neuro-Oncology
DO  - 10.1007/s11060-019-03337-2
UR  - https://doi.org/10.1007/s11060-019-03337-2
ER  -

APA

Bent, M. V. D., Azaro, A., Vos, F. D., Sepulveda, J., Yung, W. K. A., Wen, P. Y., Lassman, A. B., Joerger, M., Tabatabai, G., Rodon, J., Tiedt, R., Zhao, S., Kirsilae, T., Cheng, Y., Vicente, S., Balbin, O. A., Zhang, H., & Wick, W. (2019). A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-019-03337-2

Source records

crossref · retrieved 2026-09-26T22:05:32.005Z